TABLE 3.
Associations of TSH Levels with Participant Characteristics (Univariate)*
| Participant Characteristic | Number of Men (row percent) | P value | ||
|---|---|---|---|---|
| Decreased TSH (N=56) | Normal TSH (N=557) | Increased TSH (N=23) | ||
| Age groups | 0.37 | |||
| 49-54 | 29/366 (7.9%) | 324/366 (88.5%) | 13/366 (3.6%) | |
| 55-59 | 20/167 (12.0%) | 140/167 (83.8%) | 7/167 (4.2%) | |
| 60-64 | 4/74 (5.4%) | 69/74 (93.2%) | 1/74 (1.4%) | |
| >64 | 3/29 (10.3%) | 24/29 (82.8%) | 2/29 (6.9%) | |
| Race | 0.02 | |||
| Black | 37/342 (10.8%) | 297/342 (86.8%) | 8/342 (2.3%) | |
| Latino | 11/161 (6.8%) | 145/161 (90.1%) | 5/161 (3.1%) | |
| White | 3/91 (3.3%) | 80/91 (87.9%) | 8/91 (8.8%) | |
| Other | 5/42 (11.9%) | 35/42 (83.3%) | 2/42 (4.8%) | |
| Cigarette | 0.09 | |||
| Nonsmoker | 12/213 (5.6%) | 191/213 (89.7%) | 10/213 (4.7%) | |
| Current smoker | 44/423 (10.4%) | 366/423 (86.5%) | 13/423 (3.1%) | |
| Alcohol use | 0.38 | |||
| ≥ 2 CAGE questions | ||||
| No | 27/309 ( 8.7%) | 267/309 (86.4%) | 15/309 ( 4.9%) | |
| Yes | 28/296 ( 9.5%) | 260/296 (88.2%) | 8/296 ( 2.7%) | |
| Used illegal drugs in past 5 years | 0.08 | |||
| No | 15/251 (6.0%) | 229/251 (91.2%) | 7/251 (2.8%) | |
| Yes | 41/385 (10.7%) | 328/385 (85.2%) | 16/385 (4.2%) | |
| Used illegal drugs in past 6 months | 0.003 | |||
| No | 23/393 (5.9%) | 356/393 (90.6%) | 14/393 (3.6%) | |
| Yes | 33/241 (13.7%) | 199/241 (82.6%) | 9/241 (3.7%) | |
| Hepatitis C antibody | 0.63 | |||
| Positive | ||||
| No | 15/173 ( 8.7%) | 154/173 (89.0%) | 4/173 ( 2.3%) | |
| Yes | 38/439 ( 8.7%) | 384/439 (87.5%) | 17/439 ( 3.9%) | |
| Detectable HCV RNA | 0.38 | |||
| No | 27/309 ( 8.7%) | 191/213 (89.7%) | 5/213 ( 2.3%) | |
| Yes | 28/296 ( 9.5%) | 330/381 (86.6%) | 17/381 ( 4.5%) | |
| Ever treated with interferon | 0.51 | |||
| No | 53/586 ( 9.0%) | 513/586 (87.5%) | 20/586 ( 3.4%) | |
| Yes | 3/50 ( 6.0%) | 44/50 (88.0%) | 3/50 ( 6.0%) | |
| BMI | 0.55 | |||
| < 20 | 1/35 (2.9%) | 32/35 (91.4%) | 2/35 (5.7%) | |
| 20 to 25 | 22/237 (9.3%) | 209/237 (88.2%) | 6/237 (2.5%) | |
| > 25 to <30 | 25/243 (10.3%) | 209/243 (86.0%) | 9/243 (3.7%) | |
| ≥ 30 | 8/120 (6.7%) | 106/120 (88.3%) | 6/120 (5.0%) | |
| Bone mineral density | 0.44 | |||
| Low | ||||
| Normal | 24/295 (8.1%) | 259/295 (87.8%) | 12/295 (4.1%) | |
| 25/259 (9.7%) | 228/259 (88.0%) | 6/259 (2.3%) | ||
| HIV status | 0.20 | |||
| Seronegative | 30/274 (11.0%) | 236/274 (86.1%) | 8/274 (2.9%) | |
| Seropositive | 26/362 (7.2%) | 321/362 (88.7%) | 15/362 (4.1%) | |
| CD4 lymphocytes/mm3† | 1.0 | |||
| <200 | 5/70 ( 7.1%) | 62/70 (88.6%) | 3/70 ( 4.3%) | |
| 200-499 | 12/176 ( 6.8%) | 156/176 (88.6%) | 8/176 ( 4.5%) | |
| ≥500 | 8/107 ( 7.5%) | 95/107 (88.8%) | 4/107 ( 3.7%) | |
| Protease inhibitor | 0.65 | |||
| Ever used | ||||
| No | 8/90 (8.9%) | 78/90 (86.7%) | 4/90 (4.4%) | |
| Yes | 16/264 (6.1%) | 237/264 (89.8%) | 11/264 (4.2%) | |
*
Percentages may not total 100% due to rounding.
†
Among HIV seropositive subjects